We conclude that a higher serum HMW adiponectin level is associated with a reduced odds ratio of mild renal dysfunction in Japanese adults.
Introduction
Adiponectin, a recently discovered circulating 247-amino acid protein secreted specifically by adipose tissue, contains four differentiable domains, is present at concentrations of 5 − 30 g/mL in healthy humans, and is considered to exhibit anti-inflammatory, antiatherogenic, and antidiabetic properties [1] [2] [3] [4] . tion with an eGFR ≥ 60 mL/min/1.73 m 2 10) . In previous studies, serum HMW adiponectin was also demonstrated to be an independent risk factor for mild and moderate CKD in patients with end-stage renal disease (ESRD) 11) and in non-diabetic patients with mild to moderate CKD in several small clinical studies 12, 13) . In addition, insulin resistance and compensatory hyperinsulinemia in CKD 14) have been associated with dyslipidemia, which are important atherosclerotic risk factors 15) , and adiponectin is also inversely correlated with dyslipidemia and inflammation 16) . In contrast, despite an adverse metabolic environment in CKD, some studies have reported that serum adiponectin increases in non-obese patients 12) or type 2 diabetic patients 17) when renal function deteriorates. Moreover, to our knowledge, there are few investigations on the relationship between serum HMW adiponectin and mild renal dysfunction with an eGFR ≥ 60 mL/min/1.73 m 2 .
We took advantage of the large representative sample of Japanese adults who participated at the time of their annual health examination, and investigated whether lower serum HMW adiponectin is independently associated with mild renal dysfunction. For this, we used cross-sectional data from communitydwelling participants without clinical diabetes.
Materials and Methods

Subjects
Participants were recruited at the time of their annual health examination in a rural town with a total population of 11,136 (as of April 2002), located in Ehime prefecture, Japan, in 2002. Among the 9,133 adults aged 19 to 90 years in this population, a random sample of participants was recruited at the community-based annual medical check-up. Information on medical history, present conditions, and drugs was obtained by interview. Other characteristics, e.g., smoking and alcohol habits, and medication, were investigated by individual interviews using a structured questionnaire. Participants with an eGFR of 30 mL/min/1.73 m 2 were excluded (4 cases). Irrespective of the presence or absence of proteinuria, mildly and moderately reduced renal function was defined as an eGFR of 60 to 89.9 and 60 mL/min/ 1.73 m 2 , respectively 11) . The final study sample consisted of 1,849 eligible participants. All procedures were approved by the Ethics Committee of Ehime University School of Medicine.
Evaluation of Confounding Factors
Information on demographic characteristics and risk factors was collected using clinical files. Body mass index was calculated by dividing weight (in kilograms) by the square of the height (in meters). We measured blood pressure in the right upper arm of participants while in a sedentary position using an automatic oscillometric blood pressure recorder (BP103i; Colin, Aichi, Japan) after having rested for at least 5 min. Total cholesterol (T-C), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), fasting plasma glucose (FPG), and immuno-reactive insulin (IRI) were measured during fasting. Low-density lipoprotein cholesterol (LDL-C) levels were calculated using the Friedewald formula 18) . Participants with TG levels ≥ 400 mg/dL were excluded. The glomerular filtration rate was estimated using the following equation: eGFR 194 Age 0.287 Cr 1.094 0.739 (if female) 10) .
Statistical Analysis
Statistical analysis was performed using PASW Statistics 17.0 (Statistical Package for Social Science Japan, Inc., Tokyo, Japan). All values are expressed as the mean standard deviation (SD), unless otherwise specified. Data for TG, FPG, IRI, HOMA-IR, and serum HMW adiponectin were skewed, and log-transformed for analysis. Differences between groups were determined by ANOVA or 2 test. ANCOVA was performed with the use of a general linear model approach to determine the association between sex, age and eGFR. In these analyses, eGFR was considered a dependent variable, and four ranges of serum HMW adiponectin were considered fixed factors. Correlations between various characteristics and eGFR were determined using Pearson's correlation test, and multiple linear regression analysis was used to evaluate the contribution of risk factors, including serum HMW adiponectin, for eGFR. Logistic regression analyses were used to test significant determinants of an eGFR 70 mL/min/1.73 m 2 or 80 mL/min/1.73 m 2 with mild renal dysfunction serving as the dichotomous outcome variable. A value of p 0.05 was considered significant. 
Results
Background Factors of Subjects Categorized by eGFR
Sex and Age-Adjusted eGFR Categorized by Quartile of Log Serum HMW Adiponectin Levels
Participants with an eGFR of ≥ 60 mL/min/1.73 m 2 were divided into four groups based on quartiles of serum HMW adiponectin levels (Q1, 0.88 − 2.99 g/ mL; Q2, 3.00 − 4.92 g/mL; Q3, 4.93 − 7.95 g/mL; Q4, 7.96 − 39.2 g/mL), and it was investigated whether serum HMW adiponectin is independently associated with eGFR. By Pearson's correlation, serum HMW adiponectin was positively correlated with female sex (r 0.462, p 0.001), age (0.310, p 0.001), the prevalence of antihypertensive medication (r 0.059 p 0.011), and HDL-C (r 0.360, p Fig. 2 shows sex and age-adjusted mean values for eGFR at four levels of serum HMW adiponectin. Mean eGFR was significantly higher in the highest quartile than the lowest quartile. On the other hand, in subjects with an eGFR 60 mL/min/1.73 m 2 , there were no intergroup differences in sex and age-adjusted eGFR. Table 2 shows Pearson's correlation coefficient and multivariate linear regression analysis for eGFR with various risk factors, including serum HMW adiponectin. By Pearson's correlation, sex, smoking status, alcohol consumption, HDL-C, prevalence of antilipidemic medication, and FPG were positively correlated with eGFR, and age, BMI, SBP, DBP, prevalence of antihypertensive medication, TG, LDL-C, prevalence of CVD, and serum HMW adiponectin were inversely correlated with eGFR. Stepwise multiple linear regression analysis using eGFR as an objective variable, adjusted for confounding factors as explanatory variables, showed that serum HMW adiponectin for the highest quartile (7.96 − 39.2 g/mL). Moreover, when multiple logistic regression analysis for renal dysfunction was performed using age, antihypertensive medication, TG, LDL-C, and FPG as signifi- . Body mass index (BMI) was calculated using weight in kilograms divided by the square of the height in meters. Data for triglycerides, fasting plasma glucose, and serum HMW adiponectin were skewed, and log-transformed for analysis. HMW, high molecular weight adiponectin; eGFR, estimated glomerular filtration rate. Models adjusted for age, antihypertensive medication, triglycerides, low density lipoprotein cholesterol, and fasting plasma glucose. eGFR 194 Cr 1.094 Age 0.287 0.739 (if female). Data for triglycerides, fasting plasma glucose, and serum HMW adiponectin were skewed, and log-transformed for analysis. cant factors in Table 2 , the multivariate-adjusted odds ratio for renal dysfunction was 0.69 (95% CI, 0.51 − 0.94) for the highest quartile compared with participants with the lowest serum adiponectin quartile. Moreover, for renal dysfunction, defined as an eGFR of 70 mL/min/1.73 m 2 , the multivariate-adjusted odds ratio was 0.62 (95% CI, 0.42 − 0.91) for the highest quartile compared with participants with the lowest serum adiponectin quartile.
Association of Confounding Factors with eGFR
Discussion
Paradoxically, adiponectin has been shown to increase above normal in end-stage renal disease, peritoneal dialysis and maintenance hemodialysis [19] [20] [21] . Thus, we investigated whether this increase could happen in the early stage before CKD. In the present study, we examined the determinants of renal function (i.e., eGFR) in community-dwelling adults on the basis of the hypothesis that serum HMW adiponectin, which is reported to be a more useful marker than total adiponectin in the prediction of insulin resistance and metabolic syndrome 22) , would be associated with worsening renal function. Our results showed that eGFR was primarily determined by serum HMW adiponectin, as well as age, antihypertensive medication, TG, LDL-C, and FPG, consistent with previous studies 23, 24) . To our knowledge, this study is the first to demonstrate a relationship between serum HMW adiponectin and eGFR in the general population without CKD among Japanese adults. These findings have important clinical and public health implications because renal dysfunction is becoming common in the general Japanese population 19) . In this study, the relationship between serum adiponectin levels and confounding factors was consistent with previous studies in that adiponectin levels were positively correlated with female sex, age, and the prevalence of antihypertensive medication, and inversely correlated with BMI, smoking status, alcohol consumption, DBP, TG, and FPG 25, 26) . Thus, by adjusting for these covariates, we found that the association between serum HMW adiponectin and eGFR was positive.
Several previous studies have also shown that hypoadiponectinemia is a risk factor for developing renal dysfunction. In type 2 diabetes, plasma adiponectin is associated with GFR (evaluated by plasma iohexol clearance) of the kidney, which is at the stage of apparently normal function 27) . In mild to moderate renal dysfunction in men with type 2 diabetes, a higher serum adiponectin level is associated with reduced odds of moderate renal dysfunction 28) . In contrast, Risch et al. reported significant inverse correlations between serum adiponectin levels and eGFR (r 0.372; p 0.001). After multivariate adjustment, the associations remained significant. Moreover, subgroup analysis in patients with eGFR 60 mL/ min/1.73 m 2 showed a significant positive correlation between serum adiponectin levels and eGFR; however, after adjustments, these associations were no longer significant 29) . Also, in hemodialysis and peritoneal dialysis patients, serum adiponectin levels are more increased compared to healthy control subjects 21) , and also in non-diabetic patients with predialysis CKD, plasma adiponectin levels showed a significant inverse correlation with GFR (r 0.256, p 0.001) 30) . For renal function, a relationship between adiponectin and eGFR is paradoxical; however, recent reports have demonstrated that lower plasma adiponectin levels were associated with prevalent as well as incident CVD events in patients with mild and moderate kidney disease 30) . This protein may therefore have the potential to prevent CVD so we excluded participants with CKD of an eGFR 60 mL/min/1.73 m 2 . In our study, serum HMW adiponectin levels were significantly associated with eGFR in subjects with normal to mild renal dysfunction.
The mechanisms that lead to renal dysfunction in individuals with decreased adiponectin levels are not completely understood, but there is growing literature on serum HMW adiponectin and renal function. Several previous studies showed that serum HMW adiponectin is an insulin-sensitizing hormone and reduction of this hormone level is a useful biomarker for the prediction of insulin resistance and metabolic syndrome 22, 31) . Insulin resistance is a significant risk factor for renal dysfunction 13, 32) and increased risk factors of CVD 33) . Background mechanisms induced by insulin resistance include increased systemic oxidative stress, endothelial oxidative damage 34) , and activation of the renin-angiotensin-aldosterone system induced in adipose tissue 35) . All these factors result in decreased circulating levels of adiponectin 36) . Moreover, adiponectin also has a direct effect on the vascular system to exert vasodilator actions, and increased blood flow. Adiponectin increases NO production through two mechanisms, namely, by activation of endothelial nitric oxide synthase (eNOS) enzyme activity and via an increase in eNOS expression in endothelial cells 37, 38) . Thus, decreased adiponectin levels cause vascular dysfunction in the presence of inflammatory and oxidative vascular injuries, and enhance the predisposition to renal dysfunction.
Some limitations of this study must be considered. First, based on its cross-sectional design, the present findings are inherently limited in their ability to eliminate causal relationships between serum HMW adiponectin and eGFR. Second, we could not compare serum HMW-adiponectin with total adiponectin in the relation to eGFR because we had not measured serum total adiponectin. Third, since some of the study population had several risk factors, including hypertension, dyslipidemia, diabetes, and advanced age, we could not eliminate the possible effect of underlying diseases and medications used for these diseases on the present findings. Fourth, formulas for estimating GFR tend to be less accurate in subjects with normal renal function than in those with CKD, although ours is more accurate than serum creatinine or the Cockcroft-Gault equation 39, 40) . Fifth, our definition of eGFR is based on a single assessment of serum creatinine, which may introduce a misclassification bias; therefore, the demographics and referral source may limit generalizability.
In conclusion, the present study demonstrated that serum HMW adiponectin is associated with renal dysfunction in a general population without severe and moderate CKD. The underlying mechanism behind this relationship is unclear, but it seems to be independent of the traditional risk factors. Further prospective population-based studies are needed to investigate the mechanisms in order to answer these questions.
